Loading...
The addition (intensification) of androgen pathway inhibitors (APIs; abiraterone, apalutamide, enzalutamide) or the chemotherapy agent docetaxel to androgen-deprivation therapy (ADT) is a standard of care for the management of metastatic castration-resistant prostate cancer based on level 1 evidence of improvement in overall survival (OS). Recent studies of “triplet” therapy — ADT plus docetaxel (D) plus either darolutamide or abiraterone — show further improvement in OS. Investigators now report a systemic review and meta-analyses of 10 randomized clinical trials of ADT intensification involving 11,043 patients with metastatic castration-resistant prostate cancer and 9 unique treatments options.
In the overall population, both the ADT/D/dar…